Home > PJ (current issue) > The Society / News Centre | Search

The Pharmaceutical Journal
Vol 274 No 7349 p596
14 May 2005


Society summary


Birdsgrove House — the current situation explained

New legal requirements have had an impact on the dual use of Birdsgrove House as both rest and recuperation facility and addiction treatment centre. Bernard Kelly, the Society’s director of resources, explains the current position

Rest and recuperation

Pharmacists who are in need of rest and recuperation services or other support in times of illness or hardship are invited to contact

Beverly Nicol
Benevolent Fund Co-ordinator
01926 315994

for information and help about places that may offer facilities for convalescence or an opportunity for rest and relaxation.

Birdsgrove House is owned by the Benevolent Fund. As members may be aware, the provision of convalescence at Birdsgrove House dates back over 50 years to the immediate postwar period. In those early days of the welfare state, convalescence facilities were in great demand and a highly valued benefit. Charities such as the Benevolent Fund saw the provision of convalescence as an appropriate use of their resources.

Over the years, the demand for convalescence (or later, rest and recuperation services) declined to a low level of occupancy of the facilities. The maintenance of the house started to become a serious drain on the reserves of the Benevolent Fund.

Towards the end of the 1990s, the Council, as trustees of the Benevolent Fund, recognised this situation and sought to enhance the use of Birdsgrove House by introducing a treatment centre for pharmacists and other health professionals with addiction problems alongside but separate from the existing rest and recuperation service. The income generated by the treatment centre would help to pay for essential maintenance of the fabric of the house. For a number of years, the old and new services coexisted happily.

However, changes in legislation introduced in 2000, and subsequently amended and implemented in 2002, required that Birdsgrove House register as a private hospital and as a result changed the requirements with which it had to comply. The inspection of the house and its services was transferred to a new agency, the National Care Standards Commission, in 2003. I am sure there are many members who will be familiar with some of these changes.

During 2003 and 2004, the NCSC inspected Birdsgrove House a number of times. The reports arising indicated that, to meet the requirements of the NCSC and maintain its registered status, a great deal of work would be required to modify the fabric of the house and ways of working. Although great efforts were made to meet the required standards, in June 2004 the NCSC advised that, unless dual use as a treatment centre and as a rest and recuperation facility ceased immediately, an enforcement order would be served.

In the interests of preserving as much as possible of the activity at Birdsgrove House while also protecting the financial position of the Benevolent Fund, rest and recuperation visits booked up to August 2004 were honoured but all future bookings were suspended. The Benevolent Fund co-ordinator was asked to investigate alternative provision for those who hoped to visit the house and, where appropriate, consider contributing to the cost of alternative accommodation.

Meanwhile, the inspection role has been transferred from the NCSC to a new agency, the Healthcare Commission. We are now developing costed options which would meet the exacting new requirements, including compliance with the Disability Discrimination Act.

Members should be aware that there will be no easy options: the use of the house for rest and recuperation purposes alone would still require considerable expenditure on making the fabric of the building and ways of working compliant with requirements, without any promise of a financial return to the Benevolent Fund.

In due course, the Council, as trustees, will consider the options and decide on the future use of Birdsgrove House within the context of a contemporary interpretation of benevolence.

Back to Top


©The Pharmaceutical Journal